Financial Trade Freedom - Investing and Stock News
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
No Result
View All Result
Financial Trade Freedom - Investing and Stock News
No Result
View All Result
Home Stock

TrumpRx explained: how White House and Pfizer aim to make drugs more affordable

admin by admin
September 30, 2025
in Stock
0
TrumpRx explained: how White House and Pfizer aim to make drugs more affordable
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

The White House introduced TrumpRx, a new drug-buying website aimed at making prescription medications more affordable for Americans.

As per a Wall Street Journal report, the launch was accompanied by a major new partnership with Pfizer, which agreed to offer significant price cuts on its drugs through the platform.

President Trump has long campaigned to reduce the soaring costs of prescription drugs, and this latest move builds on his “Most Favored Nation” pricing strategy.

The goal is to bring US prices in line with the lower costs paid in other developed countries.

TrumpRx lets consumers buy directly from the government, cutting out middlemen and, hopefully, lowering prices at the pharmacy counter.

Pfizer backs TrumpRx with price cuts and US investment

Pfizer’s commitment goes beyond just discounting medications on TrumpRx. The company also plans to invest $70 billion in US research and manufacturing over the next few years.

This investment signals Pfizer’s intention to expand its presence at home while aligning new drug prices more closely with those seen abroad.

According to officials, many Pfizer drugs will be available for roughly half their typical retail cost on the new platform, making it easier for patients to afford vital treatments.

In addition to lower prices, Pfizer’s investment aims to create thousands of domestic jobs and enhance the country’s pharmaceutical innovation capacity.

Experts question impact

Despite the fanfare, some health economists and experts remain wary of how impactful TrumpRx will be in the long run.

While direct purchasing might help certain patients save money, critics caution that those on private insurance or government programs like Medicare may not benefit as much.

The platform’s range of discounted drugs could also be limited at first.

More broadly, some experts warn that pricing problems stem from systemic issues in the pharmaceutical market that a single website or partnership can’t fully address.

What this means for US healthcare

TrumpRx and the Pfizer deal are part of a broader attempt by the Trump administration to shake up the pharmaceutical industry and lower drug prices nationwide.

The strategy combines regulatory pressure, trade policy, and new pricing models to address what many Americans see as unfairly high drug costs.

If successful, this model could signal a shift in how medications are priced and accessed in the US, potentially influencing healthcare policy beyond this administration.

For now, the rollout of TrumpRx will be closely watched as a test of whether direct-to-consumer drug buying can truly deliver savings without sacrificing innovation or limiting access.

It’s a complex balance, but one with significant consequences for millions of Americans who struggle with medication costs every day.

The post TrumpRx explained: how White House and Pfizer aim to make drugs more affordable appeared first on Invezz


Previous Post

Trump’s pharma tariffs: why they’ll hit Europe and Asia differently

Next Post

Europe bulletin: EU climate goals, Starmer pushes back on ‘Reform’, stocks gain

Next Post
Europe bulletin: EU climate goals, Starmer pushes back on ‘Reform’, stocks gain

Europe bulletin: EU climate goals, Starmer pushes back on ‘Reform’, stocks gain

  • Trending
  • Comments
  • Latest
U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

February 19, 2025
How Companies Use Derivatives To Hedge Risk

How Companies Use Derivatives To Hedge Risk

February 19, 2025
KFC moves U.S. headquarters from Kentucky to Texas

KFC moves U.S. headquarters from Kentucky to Texas

February 19, 2025
As Joann Fabrics and JCPenney announce store closings, here’s what’s driving the pattern

As Joann Fabrics and JCPenney announce store closings, here’s what’s driving the pattern

February 17, 2025
Why Tesla stock is climbing over 3% on Monday

Why Tesla stock is climbing over 3% on Monday

0
From tariffs to DOGE, what companies are saying about the impact of MAGA policies

From tariffs to DOGE, what companies are saying about the impact of MAGA policies

0
Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

0
Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

0
Why Tesla stock is climbing over 3% on Monday

Why Tesla stock is climbing over 3% on Monday

October 6, 2025
US holiday spending to reach $253B as AI, BNPL reshape shopping, Adobe forecasts

US holiday spending to reach $253B as AI, BNPL reshape shopping, Adobe forecasts

October 6, 2025
Nvidia stock down around 1.5% after AMD-OpenAI deal: buy, sell or hold?

Nvidia stock down around 1.5% after AMD-OpenAI deal: buy, sell or hold?

October 6, 2025
Here’s why the Plug Power stock is having a short squeeze

Here’s why the Plug Power stock is having a short squeeze

October 6, 2025

    Get Smarter with Your Money – Sign Up for Free Financial Tips!


    Join our community of savvy savers and investors! By signing up, you'll receive weekly emails packed with personalized financial tips, budgeting hacks, and investment strategies tailored to your income level. Take control of your finances today – it’s free and only takes a minute!

    Recent News

    Why Tesla stock is climbing over 3% on Monday

    Why Tesla stock is climbing over 3% on Monday

    October 6, 2025
    US holiday spending to reach $253B as AI, BNPL reshape shopping, Adobe forecasts

    US holiday spending to reach $253B as AI, BNPL reshape shopping, Adobe forecasts

    October 6, 2025
    Nvidia stock down around 1.5% after AMD-OpenAI deal: buy, sell or hold?

    Nvidia stock down around 1.5% after AMD-OpenAI deal: buy, sell or hold?

    October 6, 2025
    Here’s why the Plug Power stock is having a short squeeze

    Here’s why the Plug Power stock is having a short squeeze

    October 6, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Investing and Stock News
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved